Formulary Watch |
All News - Page 85
FDA approves Synjardy for type 2 diabetes
August 31, 2015
FDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.
FDA expands pediatric age indication for Promacta
August 26, 2015
FDA has expanded approval of eltrombopag (Promacta, Novartis) to treat low blood platelet count in pediatric patients with chronic immune thrombocytopenic purpura.
Top 5 fastest-growing drug firms
August 26, 2015
Fortune describes the 5 fastest-growing US pharmaceutical manufacturers.
[BLOG]: Sepsis: 4 things formulary managers can do to save lives, resources
August 24, 2015
4 things formulary managers can do to save lives and resources.
Top 4 future impacts of 3D printed drugs
August 20, 2015
FDA’s approval of the first 3D-printed pill – Spritam to control epileptic seizures – will have a major impact on the medical and pharmaceutical community as a whole.
Top 5 things to know about “female Viagra”
August 20, 2015
FDA’s long-awaited approval of Addyi (flibanserin) to treat hypoactive sexual desire disorder in premenopausal women, is significant for the prescribing community.
Diabetes drug may reduce stroke, CV deaths
August 20, 2015
Jardiance is the first diabetes drug that has also been shown to lower strokes, heart attacks and cardiovascular deaths, according to a new study.
FDA approves new Onsolis formulation
August 18, 2015
FDA has approved sNDA for new formulation of fentanyl buccal soluble film (Onsolis, BioDelivery Sciences International) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.
FDA's Avastin rules may not be necessary
August 18, 2015
While FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.
FDA approves OxyContin for some pediatric patients
August 14, 2015
FDA recently granted special approval of pediatric use of OxyContin in patients aged 11 to 16 years, under specific conditions.
Real-world Actemra data show lower rate of some SAEs vs. clinical trials in RA
August 12, 2015
A study of tocilizumab (Actemra) in the treatment of rheumatoid arthritis (RA) found that the number of serious adverse events (SAEs) found in postmarketing data were similar to other populations from clinical trials and epidemiology data.
New insulin drug to enter crowded market
August 10, 2015
Novo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
5 reasons to be concerned over proposed Medicare rule on biosimilar coding
August 10, 2015
A Medicare reimbursement policy proposing that multiple biosimilars have the same pricing J-code for Medicare reimbursement purposes could ultimately result in fewer treatment options, according to a group representing the industry.
Top 5 tips to eliminate prescribing errors
August 6, 2015
Surprisingly, giving prescriptions to the wrong patients is still common in community pharmacies across the U.S. According to the Institute for Safe Medication Practices (ISMP), this error occurs about once in every 1,000 prescriptions dispensed.
FDA approves new topical rosacea treatment
August 6, 2015
FDA has approved azelaic acid (Finacea, Bayer HealthCare) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Pharmacy companies underinvest in cancer drugs
August 6, 2015
Pharmaceutical firms “underinvest” in long-term research to develop new cancer-fighting drugs because of the time and expense, according to a new study.
FDA approves first 3D epilepsy drug
August 6, 2015
FDA approved epilepsy drug levetiracetam (Spritam), the first FDA-approved drug that utilizes three-dimensional printing (3DP).
Unichem recalls 1 lot of blood pressure drug
August 6, 2015
Unichem Pharmaceuticals issued a voluntary recall of Hydrochlorothiazide Tablets 25 mg, 1,000-count bottle. The precautionary measure is due to the identification of a Clopidogrel tablet found in a bottle at one pharmacy.
Drug sales to top $1.3 trillion
August 6, 2015
Global sales of pharmaceuticals will soar to $1.3 trillion in 2018, led by new cancer and specialty drug introductions, a new report found.
MS drug linked to rare brain infection
August 6, 2015
FDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).
Bleeding disorder drug shows positive results
August 5, 2015
After positive phase 3 trial data for its treatment for the bleeding disorder von Willebrand disease, Baxalta Inc. is awaiting FDA approval for the drug.
Intranasal naloxone has potential to be first in US to treat opioid overdose
July 31, 2015
FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States.
8 high-profile FDA approvals
July 30, 2015
There have been 8 high-profile FDA approvals in the last few weeks. Here is an overview.
FDA approves Daklinza for hepatitis C genotype 3
July 27, 2015
On July 24, FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections.
Skin cancer drug Odomzo gets FDA approval
July 27, 2015
FDA has approved sonidegib (Odomzo, Novartis) for locally advanced basal cell carcinoma.
Antibiotic use in kids: More misconceptions among Medicaid parents
July 27, 2015
Misconceptions about antibiotic use persist and continue to be more prevalent among parents of Medicaid-insured children, according to a study published in Pediatrics.
FDA approves Technivie for treatment of hepatitis C virus genotype 4 infections
July 27, 2015
FDA has approved ombitsavir, paritaprevir and ritonavir (Technivie, AbbVie) for the treatment of hepatitis C virus genotype 4 infections.
The first PCSK9 inhibitor approval: 5 lessons
July 27, 2015
With FDA’s approval of Praluent (alirocumab) injection, the first in a new class of injectable cholesterol-lowering drugs called PCSK9 inhibitors, comes the need for a utilization management approach.
